221 related articles for article (PubMed ID: 38279242)
21. CDK4/6 inhibitors in HER2-positive breast cancer.
Corona SP; Ravelli A; Cretella D; Cappelletti MR; Zanotti L; Dester M; Gobbi A; Petronini PG; Generali D
Crit Rev Oncol Hematol; 2017 Apr; 112():208-214. PubMed ID: 28325261
[TBL] [Abstract][Full Text] [Related]
22. A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
Fedele P; Sanna V; Fancellu A; Cinieri S
Expert Opin Pharmacother; 2019 Dec; 20(18):2305-2315. PubMed ID: 31610139
[No Abstract] [Full Text] [Related]
23. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
Rugo HS
Clin Adv Hematol Oncol; 2019 Oct; 17(10):555-558. PubMed ID: 31730581
[No Abstract] [Full Text] [Related]
25. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
Cruz M; Reinert T; Cristofanilli M
Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
[TBL] [Abstract][Full Text] [Related]
26. CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
Di Cosimo S; Porcu L; Cardoso F
Breast; 2021 Feb; 55():75-78. PubMed ID: 33352521
[TBL] [Abstract][Full Text] [Related]
27. Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.
Koirala N; Dey N; Aske J; De P
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742993
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
29. Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer.
Cunningham NC; Turner NC
Cancer Cell; 2021 Mar; 39(3):307-309. PubMed ID: 33689702
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
31. The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Meegdes M; Geurts SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Teeuwen NJA; de Boer M; Tjan-Heijnen VCG
Int J Cancer; 2022 Jan; 150(1):124-131. PubMed ID: 34460112
[TBL] [Abstract][Full Text] [Related]
32. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
34. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.
Cortés J; Im SA; Holgado E; Perez-Garcia JM; Schmid P; Chavez-MacGregor M
Cancer Treat Rev; 2017 Dec; 61():53-60. PubMed ID: 29100169
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Yıldırım HÇ; Mutlu E; Chalabiyev E; Özen M; Keskinkılıç M; Ön S; Çelebi A; Dursun B; Acar Ö; Kahraman S; Aykan MB; Kaman Ö; Doğan A; Erdoğan AP; Melisa Celayir Ö; Günenç D; Güven DC; Vedat Bayoğlu İ; Yavuzşen T; Hacıbekiroğlu İ; İnanç M; Kılıçkap S; Yalçın Ş; Aksoy S
Breast; 2022 Dec; 66():85-88. PubMed ID: 36208540
[TBL] [Abstract][Full Text] [Related]
36. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
37. [Inhibitors of cyclin-dependent kinases (CDK) - a new group of medicines in therapy of advanced breast cancer].
Sarosiek T
Pol Merkur Lekarski; 2018 Jan; 44(259):5-9. PubMed ID: 29374415
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
39. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
[TBL] [Abstract][Full Text] [Related]
40. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
